The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines

Abstract

Fluoropyrimidines (FP) are given in the combination treatment of the advanced disease or as monotherapy in the neo-adjuvant and adjuvant treatment of colorectal cancerand other solid tumors including breast, head and neck and gastric cancer. FP present a narrow therapeutic index with 10 to 26% of patients experiencing acute severe or life-threatening toxicity. With the high number of patients receiving FP-based therapies, and the significant effects of toxicities on their quality of life, the prevention of FP-related adverse events is of major clinical interest. Host genetic variants in the rate limiting enzyme dihydropyrimidine dehydrogenase (DPYD) gene are related to the occurrence of extremely severe, early onset toxicity in FP treated patients. The pre-treatment diagnostic test of 4 DPYD genetic polymorphisms is suggested by the currently available pharmacogenetic guidelines. Several prospective implementation projects are ongoing to support the introduction of up-front genotyping of the patients in clinical practice. Multiple pharmacogenetic studies tried to assess the predictive role of other polymorphisms in genes involved in the FP pharmacokinetics/pharmacodynamic pathways, TYMS and MTHFR, but no additional clinically validated genetic markers of toxicity are available to date. The development of next-generation sequencing platforms opens new possibilities to highlight previously unreported genetic markers. Moreover, the investigation of the genetic variation in the patients immunological system, a pivotal target in cancer treatment, could bring notable advances in the field. This review will describe the most recent literature on the use of pharmacogenetics to increase the safety of a treatment based on FP administration in colorectal cancer patients.

Keywords

Fluoropyrimidines / pharmacogenetics / colorectal cancer / toxicity / DPYD / TYMS / MTHFR

References

[1] Pirmohamed M,Meakin S,Scott AK.Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients..BMJ2004;329:15-9 PMCID:PMC443443

[2] Lazarou J,Corey PN.Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies..JAMA1998;279:1200-5

[3] Rottenkolber D,Rottenkolber M,Saljé K.Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations..Pharmacoepidemiol Drug Saf2011;20:626-34

[4] Gyllensten H,Hägg S,Petzold M.Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adults..PLoS One2014;9:e92061 PMCID:PMC3956863

[5] Latremouille-Viau D,Guerin A,Wang E.The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States..J Med Econ2017;20:54-62

[6] Meyerhardt JA.Systemic therapy for colorectal cancer..N Engl J Med2005;352:476-87

[7] Twelves C,Nowacki MP,Burris H.Capecitabine as adjuvant treatment for stage III colon cancer..N Engl J Med2005;352:2696-704

[8] André T,Louvet C,Gamelin E.Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1..J Clin Oncol2007;25:3732-8

[9] Sugihara K,Shimada Y,Gomi K.Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies..Cancer Med2012;1:198-206 PMCID:PMC3544454

[10] Chiara DF,Rossana R,Fabrizio E.DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients..JMCM2018;1:143-50

[11] Van Cutsem E,Nordlinger B.Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up..Ann Oncol2014;25:iii1-9

[12] Danesi R,Ciccolini J,Schwab M.Prevention of fluoropyrimidine toxicity: do we still have to try our patient’s luck?.Ann Oncol2017;28:183

[13] Deenen MJ.Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer..Ann Oncol2017;28:184

[14] Boige V,Alexandre P,Landolfi S.DPYD genotyping to predict adverse events following treatment with flourouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial..JAMA Oncol2016;

[15] Lee AM,Pavey E,Sargent DJ.DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)..J Natl Cancer Inst2014;106:dju298 PMCID:PMC4271081

[16] Toffoli G,Buonadonna A,De Paoli A.Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines..Int J Cancer2015;137:2971-80

[17] Deenen MJ,Cats A,Severens JL.Upfront Genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis..J Clin Oncol2016;34:227-34

[18] Henricks LM,Meulendijks D,Cats A.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score..Pharmacogenomics2015;16:1277-86

[19] Amstutz U,Offer SM,Schellens JHM.Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update..Clin Pharmacol Ther2018;103:210-6 PMCID:PMC5760397

[20] Lunenburg CATC,Dreussi E,Fiocco M.Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers..Eur J Cancer2018;104:210-8

[21] Meulendijks D,Sonke GS,Froehlich TK.Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data..Lancet Oncol2015;16:1639-50

[22] Lunenburg CA,Gelderblom H,Swen JJ.Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients..Pharmacogenomics2016;17:721-9

[23] Innocenti F.DPYD variants to predict 5-FU toxicity: the ultimate proof..J Natl Cancer Inst2014;106:dju351

[24] Roncato R,Montico M,Giodini L.Cost evaluation of irinotecan-related toxicities associated with the UGT1A1*28 patient genotype..Clin Pharmacol Ther2017;102:123-30

[25] Toffoli G,Polesel J,Sartor F.The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice..Clin Pharmacol Ther2018;

[26] Henricks LM,de Man FM,Frederix GWJ.A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy..Eur J Cancer2019;107:60-7

[27] Keeling NJ,West-Strum D,Haidar CE.Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers..Genet Med.2017; PMCID:PMC5920773

[28] Cecchin E,Guchelaar HJ.Ubiquitous pharmacogenomics (U-PGx): the time for implementation is now. An Horizon2020 Program to drive pharmacogenomics into clinical practice..Curr Pharm Biotechnol2017;18:204-9

[29] van der Wouden CH,Cecchin E,Dávila-Fajardo CL.Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium..Clin Pharmacol Ther2017;101:341-58

[30] Duthie SJ.Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis..J Inherit Metab Dis2011;34:101-9

[31] De Mattia E.C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation..Eur J Cancer2009;45:1333-51

[32] Toffoli G,Gaidano G,Boiocchi M.Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase..Int J Biol Markers2003;18:218-21

[33] Boisdron-Celle M,Faroux R,Metges JP.Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach..Semin Oncol2017;44:13-23

[34] Terrazzino S,Del Re M,Canonico PL.DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis..Pharmacogenomics2013;14:1255-72

[35] Falvella FS,Martinetti A,Iacovelli R.DPD and UGT1A1 deficiency in colorectalcancerpatientsreceivingtriple tchemotherapy with fluoropyrimidines, oxaliplatin and irinotecan..Br J Clin Pharmacol2015;80:581-8 PMCID:PMC4574842

[36] Madi A,Maughan TS,Meade AM.Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy..Eur J Cancer2018;102:31-9

[37] Pellicer M,García MI,García-Alfonso P.Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity..Pharmacogenomics2017;18:1215-23

[38] Ruzzo A,Galli F,Rulli E.Dihydropyrimidinedehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients..Br J Cancer2017;117:1269-77 PMCID:PMC5709672

[39] Rosmarin D,Church D,Jones A.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis..J Clin Oncol2014;32:1031-9 PMCID:PMC4879695

[40] Offer SM,Fossum C,Diasio RB.Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity..Cancer Res2013;73:1958-68 PMCID:PMC3602211

[41] He YF,Zhang X,Li S.Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients..J Clin Pharm Ther2008;33:307-14

[42] Offer SM,Wegner NJ,Butterfield GL.Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity..Cancer Res2014;74:2545-54 PMCID:PMC4012613

[43] Nie Q,Tapper EE,Bouchonville KJ.Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity..Clin Pharmacol Ther2017;102:662-70 PMCID:PMC6138243

[44] Launay M,Duval M,Milano G.Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer..Br J Clin Pharmacol2016;81:124-30 PMCID:PMC4693577

[45] Launay M,Fournel C,Dupuis C.Upfront DPD deficiency detection to secure 5-FU administration: part 2-application to head-and-neck cancer patients..Clin Cancer Drugs2017;4:122-8 PMCID:PMC5906055

[46] Meulendijks D,Jacobs BAW,Deenen MJ.Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity..Br J Cancer2017;116:1415-24 PMCID:PMC5520099

[47] Etienne-Grimaldi MC,Beroud C,van Kuilenburg A.New advances in DPYD genotype and risk of severe toxicity under capecitabine..PLoS One2017;12:e0175998 PMCID:PMC5421769

[48] Botticelli A,Strigari L,Di Pietro FR.A nomogram to predict 5-fluorouracil toxicity: whenpharmacogenomicsmeets the patient..Anticancer Drugs2017;28:55-6

[49] Meulendijks D,Cats A,Joerger M.Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies..Pharmacogenomics J2017;17:441-51

[50] Cecchin E,Campagnutta E,Toffoli G.Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian population..Int J Biol Markers2004;19:160-3

[51] Longley DB,Johnston PG.5-fluorouracil: mechanisms of action and clinical strategies..Nat Rev Cancer2003;3:330-8

[52] De Mattia E,Toffoli G.Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy..Drug Resist Updat2015;20:39-70

[53] Lima A,Sousa H,Medeiros R.Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics..Pharmacogenomics2013;14:1337-51

[54] Jennings BA,Willis G,Wawruch P.Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis..Pharmacogenet Genomics2012;22:290-304

[55] Campbell JM,Bateman E,Keefe DM.Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses..Pharmacogenomics J2017;17:21-8

[56] Smyth E,Cunningham D,Soong R.Pharmacogenetic analysis of the UK MRC (Medical Research Council) MAGIC trial: association of polymorphisms with toxicity and survival in patients treated with perioperative epirubicin, cisplatin, and 5-fluorouracil (ECF) chemotherapy..Clin Cancer Res2017;23:7543-9 PMCID:PMC6175041

[57] Tan BR,Myerson RJ,Trinkaus K.Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma..J Clin Oncol2011;29:875-83 PMCID:PMC3068061

[58] Rosmarin D,Pagnamenta A,Pita G.A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS..Gut2015;64:111-20 PMCID:PMC4283622

[59] García-González X,García MI,Robles L.Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer..Oncotarget2015;6:6422-30 PMCID:PMC4467446

[60] Cecchin E,Pucciarelli S,Canzonieri V.Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy..Pharmacogenomics J2011;11:214-26

[61] Libra M,Talamini R,Sartor F.Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy..BMC Cancer2004;4:11 PMCID:PMC400738

[62] Cecchin E,Nobili S,De Mattia E.MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin..Pharmacogenomics J2015;15:219-25

[63] Pellicer M,García MI,Grávalos C.Identification of new SNPs associated with severe toxicity to capecitabine..Pharmacol Res2017;120:133-7

[64] Ose J,Balavarca Y,Scherer D.Pathway analysis of genetic variants in folate-mediated one-carbon metabolism-related genes and survival in a prospectively followed cohort of colorectal cancer patients..Cancer Med2018; PMCID:PMC6051204

[65] Ichikawa W,Suto K,Hirayama R.Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen..Clin Cancer Res2006;12:3928-34

[66] Tsunoda A,Watanabe M,Ooyama A.Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study..Ann Oncol2011;22:355-61

[67] Gusella M,Bolzonella C,Padrini R.Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays..Genet Test Mol Biomarkers2011;15:691-5

[68] Jennings BA,Skinner J,Chu GS.Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines..PLoS One2013;8:e78053 PMCID:PMC3805522

[69] Loganayagam A,Corrigan A,Lewis CM.Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity..Br J Cancer2013;108:2505-15 PMCID:PMC3694243

[70] Caronia D,Sastre J,García-Sáenz JA.A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome..Clin Cancer Res2011;17:2006-13

[71] Dahan L,Evrard A,Tibbitts J.Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications..J Clin Oncol2012;30:e41-44

[72] Lévi F,Saffroy R,Boige V.Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)..Br J Cancer2017;117:965-73 PMCID:PMC5625679

[73] Yap YS,Syn N,Chia JWK.Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial..JAMA Oncol2017;3:1538-45 PMCID:PMC5710192

[74] De Mattia E,Montico M,Guillemette C.Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-related gastrointestinal toxicity in metastatic colorectal cancer patients..Front Pharmacol2018;9:367 PMCID:PMC5908896

[75] Garziera M,De Mattia E,Cecchin E.HLA-G 3’UTR polymorphisms predict drug-induced G3-4 toxicity related to folinic acid/5-fluorouracil/oxaliplatin (FOLFOX4) chemotherapy in non-metastatic colorectal cancer..Int J Mol Sci2017;18:E1366 PMCID:PMC5535859

[76] Garziera M,Cecchin E,Nobili S.HLA-G 3’UTR polymorphisms impact the prognosis of stage II-III CRC patients in fluoropyrimidine-based treatment..PLoS One2015;10:e0144000 PMCID:PMC4669157

[77] De Mattia E,Montico M,Zanusso C.A clinical-genetic score to identify surgically resected colorectal cancer patients benefiting from an adjuvant fluoropyrimidine-based therapy..Front Pharmacol2018;9:1101 PMCID:PMC6180157

[78] Re VD,Zorzi MD,Racanelli V.Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy..PLoS One2014;9:e84940 PMCID:PMC3908861

[79] Abad A,Viéitez JM,García Alfonso P.Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial..Ann Oncol2018;29:439-44

[80] McLeod HL,Marsh S,King CR.Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741..J Clin Oncol2010;28:3227-33 PMCID:PMC2903324

[81] Toffoli G,Gasparini G,Azzarello G.Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer..J Clin Oncol2010;28:866-71 PMCID:PMC4872310

[82] Di Francia R,Berretta M,Orlando C.Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics..Clin Chem Lab Med2010;48:447-59

[83] Afzal S,Vainer B,Andersen JT.Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients..Clin Cancer Res2011;17:3822-9

[84] Kozyra M,Lauschke VM.Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response..Genet Med2017;19:20-9